Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

Abstract Despite the widespread use of carfilzomib (K) in relapsed/refractory multiple myeloma (RRMM), there is no consensus on optimal K dose in milligrams per square meter (mg/m2) or dosing schedule. We assessed three modern K prescribing patterns in RRMM using a large United States electronic hea...

Full description

Bibliographic Details
Published in:	Blood Cancer Journal
Main Authors:	Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Anosheh Afghahi, Aimaz Afrough, Murali Janakiram, Bo Wang, Andrew J. Cowan, Adam S. Sperling, Larry D. Anderson, S. Vincent Rajkumar, Gurbakhash Kaur
Format:	Article
Language:	English
Published:	Nature Publishing Group 2025-03-01
Online Access:	https://doi.org/10.1038/s41408-025-01256-2

Similar Items

Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma
by: Lin Wang, et al.
Published: (2025-12-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
by: Philippe Moreau, et al.
Published: (2023-03-01)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
by: Marcelo Capra, et al.
Published: (2021-10-01)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS
by: Ecenur Guder Arslan, et al.
Published: (2023-10-01)

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024-11-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
by: Fieke W. Hoff, et al.
Published: (2024-03-01)

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
by: Ajai Chari, et al.
Published: (2018-07-01)

P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
by: C. Hulin, et al.
Published: (2022-06-01)

Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
by: Jesus G. Berdeja, et al.
Published: (2015-05-01)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
by: H. Quach, et al.
Published: (2022-06-01)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-03-01)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
by: Elisabetta Antonioli, et al.
Published: (2023-04-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study
by: Cyrille Hulin, et al.
Published: (2024-08-01)

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
by: Elisabet E. Manasanch, et al.
Published: (2020-05-01)

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
by: SV Semochkin, et al.
Published: (2018-12-01)

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
by: Rahul Banerjee, et al.
Published: (2023-11-01)

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
by: M. Turgut, et al.
Published: (2020-10-01)

A PHASE 3, TWO-STAGE, RANDOMIZED STUDY OF MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VERSUS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-2
by: PGR Md, et al.
Published: (2023-10-01)

Cardiac and renal complications of carfilzomib in patients with multiple myeloma
by: Meletios A. Dimopoulos, et al.
Published: (2017-02-01)

Carfilzomib‐associated pulmonary arterial hypertension in multiple myeloma
by: Jenny Z. Yang, et al.
Published: (2021-10-01)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01)

Targeted treatments for multiple myeloma: specific role of carfilzomib
by: Sugumar D, et al.
Published: (2015-01-01)

P173 | CLINICAL EFFICACY OF ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2025 DATA UPDATE
by: D. Derudas, et al.
Published: (2025-09-01)

Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis
by: Wenhao Yang, et al.
Published: (2025-10-01)

Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma—A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
by: Tobias S. Slørdahl, et al.
Published: (2025-02-01)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
by: Deborah Osafehinti, et al.
Published: (2019-01-01)

Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study
by: Kamel Laribi, et al.
Published: (2024-02-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
by: Joshua Richter, et al.
Published: (2023-04-01)

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
by: Surbhi Sidana, et al.
Published: (2023-09-01)

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
by: I. Attucci, et al.
Published: (2023-05-01)

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-11-01)

Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management
by: Yi Gao, et al.
Published: (2025-03-01)

Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma
by: Samia Shabnaz, et al.
Published: (2024-05-01)

Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib
by: Vladimir Liberman, et al.
Published: (2016-07-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis
by: Thierry Facon, et al.
Published: (2023-08-01)

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
by: Thomas Martin, et al.
Published: (2023-05-01)